Table 3.
Parameters | Total n = 162 (%) | Bone metastasis n = 47 (%) | Brain metastasis n = 39 (%) | Liver metastasis n = 24 (%) | Lung metastasis n = 52 (%) | P-value |
---|---|---|---|---|---|---|
GNMT (T) | 0.016 | |||||
Negative | 153 (94.4) | 47 (100.0) | 37 (94.9) | 24 (100.0) | 45 (86.5) | |
Positive | 9 (5.6) | 0 (0.0) | 2 (5.1) | 0 (0.0) | 7 (13.5) | |
SARDH (T) | 0.730 | |||||
Negative | 158 (97.5) | 45 (95.7) | 38 (97.4) | 24 (100.0) | 51 (98.1) | |
Positive | 4 (2.5) | 2 (4.3) | 1 (2.8) | 0 (0.0) | 1 (1.9) | |
PIPOX (T) | 0.069 | |||||
Negative | 125 (77.2) | 35 (74.5) | 35 (89.5) | 20 (83.3) | 35 (67.3) | |
Positive | 37 (22.8) | 12 (25.5) | 4 (10.3) | 4 (16.7) | 17 (32.7) | |
PIPOX (S) | 0.533 | |||||
Negative | 152 (93.8) | 43 (91.5) | 36 (92.3) | 24 (100.0) | 49 (94.2) | |
Positive | 10 (6.2) | 4 (8.5) | 3 (7.7) | 0 (0.0) | 3 (5.8) |
GNMT, glycine N-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic acid oxidase; T, tumor; S, stroma.